A study published in the British Journal of Gastroenterology shows that a novel gastroscopic treatment, called SCO, was effective in reducing the severity of scoliotic complications associated with COVID-19.
The study, which followed about 2,400 patients for six months, found that patients who had undergone SCO had significantly fewer complications.
The patients who were given a COVID treatment were also able to reduce their risk of developing the complication, with the average reduction in SCO-related complications being almost 25%.
The researchers concluded that SCO is a promising treatment for SCO patients who do not have any other treatment options.
A study in 2016 found that COVID patients who received SCO saw a 30% reduction in COVID mortality, compared to patients who did not receive the treatment.
The team of researchers found that SCOP therapy was equally effective in controlling scolitis and COVID complications.
The researchers noted that the patients were treated with a wide range of drugs, including anti-inflammatory drugs, anti-coagulants, antihistamines, and anti-fungal agents.
This is a first for the field of gastroenterology, where the drug used in SCOP is called furosemide.
SCOP has shown promise in a number of other cases, but its effectiveness has not been well documented.
The study also found that the SCOP treatment led to fewer complications compared to a placebo, and was equally or more effective than other COVID treatments, including the fluoxetine and amoxicillin-clavulanate-paraquinolone (ICV) treatments.
The authors suggest that this trial is an important first step toward making SCOP a standard of care for COVID.
The authors wrote that the trials were not designed to prove that SCOM or SCOP are the most effective treatments for COVI patients.
However, they noted that a similar study in the United Kingdom had found that a treatment called CCL-1 inhibitor was equally as effective as SCO in reducing COVID death rates among patients with SCO.
“The current study demonstrates that SCOPE is a feasible and safe, relatively safe, and relatively effective treatment option for COV-19,” the researchers wrote.
“Our findings suggest that SCOME and/or SCOP may offer a viable option for the management of COVID, even for those patients who have not responded to other therapies.”
The results of this study should encourage researchers to continue to look for alternative COVID drugs to treat COVID related complications.
There are no new therapies in the pipeline that are more effective in treating COVID than SCO and are currently available for sale in the U.S.